Clinical evidence SELECT cardiovascular outcomes SELECT enrolled 17,604 adults aged 45 years with established atherosclerotic cardiovascular disease (prior MI, stroke, or symptomatic peripheral arterial disease) and BMI 27 kg/m, but without diabetes, randomizing them 1:1 to semaglutide 2.4 mg SC weekly (after titration) or placebo on top of standard CV therapies
This includes regular monitoring, personalized adjustments, and ongoing support
Holistic Approach : We address all aspects of health, including nutrition, exercise, mental well-being, and more, to provide a well-rounded program
Given liraglutides mechanism of action causes increased satiety, there may be an increased risk of young children developing eating disorders